Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | VNN1 | O95497 | 13/20 | 0.59 |
| ▸ | ECE1 | P42892 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantothenic Acid SCHEMBL21175997 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL29872649 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL21547 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL5436 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL14126322 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL5437 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL21114380 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL7016631 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL23275570 | 0.97 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL20592074 | 0.97 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874557-A | Method for refining D-pantothenic acid from fermentation liquor | 诸城市浩天药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-116463272-A | Genetically engineered bacterium for high yield of D-pantothenic acid, construction method and application | 浙江工业大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-112331934-A | Device for replacing and updating lead bush of lead-acid storage battery pole | 戴广金 | 2021-02-05 | — | — | CN | disclosed |
| CN-211428299-U | Device for replacing and updating lead bush of lead-acid storage battery pole | 戴广金 | 2020-09-04 | — | — | CN | disclosed |
| US-20190224170-A1 | THERAPIES AND METHODS TO TREAT INFLAMMATORY GASTROINTESTINAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224170-A1 | THERAPIES AND METHODS TO TREAT INFLAMMATORY GASTROINTESTINAL DISEASES AND DISORDERS | FABP2, VNN1, APC | PTGS1 71/4885KCNH2 4611/4885VNN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.